Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
The appointments of Dr. Alain Pluquet as Chairman of the Board and Mr. Michael Tillmann as Independent Director brings extensive industrial expertise to help develop Axithra’s long-term strategy
An estimated 50 million people in Europe regularly go for a run, including almost 20% of the Belgian population. While most might not be running marathons at an Olympic pace, the chance of getting injured can feel inevitable to any runner. This fear is justified, as around half of all runners experience at least one injury annually. But what’s driving this unsettling statistic, and how can runners potentially reduce the likelihood of a dreaded injury spell?
For scientists or budding entrepreneurs with the next big idea in sports tech, the road from conceptualization to product can seem perilous, with many pitfalls along the way. To stand a chance at getting your research out of the lab and into the hands of athletes, it’s essential to start off on the right foot.
Read on to see how the collaboration of scientists and sports tech development experts is helping this unique ecosystem in Belgium to flourish.
Children increasingly seek the comfort and entertainment of television, tablets and smartphones rather than playing outside. This reduction in physical activity has accelerated over the last few decades and has detrimental effects for children later in life. They are the future, so studying their development and lifestyle gives us a forecast of where we are heading. Are we moving towards a sedentary population? And if so, how can we alter our course?
Training session after training session, top athletes must push themselves to the limits to test their bodies. Although pain is a clear emergency signal, athletes in pain may push themselves even further. This makes them vulnerable to injuries and severe pain conditions including acute and chronic lower back pain. Although there are several treatment options to alleviate the symptoms, the treatment of acute and chronic pain is not straightforward. A multidisciplinary approach is required, and more treatment options are needed that focus on treating the underlying cause.
Artificial intelligence (AI) and machine learning have great potential to improve people’s lives. From supporting data analysis in research to providing more accurate and quicker diagnostic tools. But their interior workings are questioned by many and understood by few. New models are needed to solve current shortcomings and causal AI might be our way out. By offering a peek inside the black box, it creates opportunities to implement AI in high-risk settings such as healthcare. But how far along are we and where is this journey taking us?
At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.
Microalgae have been proposed as a potential source for numerous products, ranging from proteins used in nutrition to mycosporine-like amino acids (MAA) that could be used in sunscreens to absorb ultraviolet (UV) light. However, one of the major constraints to using microalgae-based products is their low production of high-value products like MAA. GeneBEcon, a Horizon Europe-funded project, investigates the potential to increase the production of valuable compounds in microalgae through gene editing in order to enable a more sustainable bioeconomy in Europe.
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
The appointments of Dr. Alain Pluquet as Chairman of the Board and Mr. Michael Tillmann as Independent Director brings extensive industrial expertise to help develop Axithra’s long-term strategy
An estimated 50 million people in Europe regularly go for a run, including almost 20% of the Belgian population. While most might not be running marathons at an Olympic pace, the chance of getting injured can feel inevitable to any runner. This fear is justified, as around half of all runners experience at least one injury annually. But what’s driving this unsettling statistic, and how can runners potentially reduce the likelihood of a dreaded injury spell?
For scientists or budding entrepreneurs with the next big idea in sports tech, the road from conceptualization to product can seem perilous, with many pitfalls along the way. To stand a chance at getting your research out of the lab and into the hands of athletes, it’s essential to start off on the right foot.
Read on to see how the collaboration of scientists and sports tech development experts is helping this unique ecosystem in Belgium to flourish.
Children increasingly seek the comfort and entertainment of television, tablets and smartphones rather than playing outside. This reduction in physical activity has accelerated over the last few decades and has detrimental effects for children later in life. They are the future, so studying their development and lifestyle gives us a forecast of where we are heading. Are we moving towards a sedentary population? And if so, how can we alter our course?
Training session after training session, top athletes must push themselves to the limits to test their bodies. Although pain is a clear emergency signal, athletes in pain may push themselves even further. This makes them vulnerable to injuries and severe pain conditions including acute and chronic lower back pain. Although there are several treatment options to alleviate the symptoms, the treatment of acute and chronic pain is not straightforward. A multidisciplinary approach is required, and more treatment options are needed that focus on treating the underlying cause.
Artificial intelligence (AI) and machine learning have great potential to improve people’s lives. From supporting data analysis in research to providing more accurate and quicker diagnostic tools. But their interior workings are questioned by many and understood by few. New models are needed to solve current shortcomings and causal AI might be our way out. By offering a peek inside the black box, it creates opportunities to implement AI in high-risk settings such as healthcare. But how far along are we and where is this journey taking us?
At the heart of Europe, Benelux is like a drop of ink spreading its influence internationally; an in-depth study conducted by KBC Securities placed Belgium as Europe’s leading country for biotech in 2024. This year's edition of Knowledge for Growth, hosted by the life sciences cluster flanders.bio celebrating their 20th anniversary, highlighted the vibrant Flemish life sciences ecosystem. The event took place in Antwerp, Belgium on May 15th and 16th, where industry professionals, scientists, investors, policymakers, and more gathered to share their knowledge and insights and answer why the region of Flanders, and the Benelux overall, are doing so well in this vibrant landscape.
Microalgae have been proposed as a potential source for numerous products, ranging from proteins used in nutrition to mycosporine-like amino acids (MAA) that could be used in sunscreens to absorb ultraviolet (UV) light. However, one of the major constraints to using microalgae-based products is their low production of high-value products like MAA. GeneBEcon, a Horizon Europe-funded project, investigates the potential to increase the production of valuable compounds in microalgae through gene editing in order to enable a more sustainable bioeconomy in Europe.